Duchenne cardiomyopathy: targeting ROS and NOX4 as a promising therapeutic strategy

Expert Opin Ther Targets. 2023 Feb;27(2):91-95. doi: 10.1080/14728222.2023.2187287. Epub 2023 Mar 23.

Authors

Maurilio Sampaolesi^{1

2}, Stefan Janssens³, Robin Duelen^{1

3}

Affiliations

¹ Translational Cardiomyology, Stem Cell and Developmental Biology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
² Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy.
³ Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.

PMID: 36951439
DOI: 10.1080/14728222.2023.2187287

No abstract available

Keywords: Duchenne muscular dystrophy; NOX4; ROS; cardiomyopathy; therapeutics.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Cardiomyopathies* / therapy
Humans
Muscular Dystrophy, Duchenne* / drug therapy
NADPH Oxidase 4
Reactive Oxygen Species

Substances

Reactive Oxygen Species
NOX4 protein, human
NADPH Oxidase 4